Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2352-2357
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2352
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2352
Table 3 The adverse events of three approved regimen for metastatic pancreatic cancer reported in NEJM 2011 and ASCO 2013
| Adverse events | Gemcitabine | FOLFIRINOX | Gemcitabine/nab-paclitaxel |
| Neutropenia | 21% | 45.7% | 38% |
| Febrile neutropenia | 1.2% | 5.4% | 3% |
| Thrombocytopenia | 3.6% | 9.1% | 13% |
| Fatigue | 17.8% | 23.6% | 17% |
| Diarrhea | 1.8% | 12.7% | 6% |
| Peripheral neuropathy | 0% | 9.0% | 17% |
- Citation: Ghosn M, Kourie HR, Karak FE, Hanna C, Antoun J, Nasr D. Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 2014; 20(9): 2352-2357
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2352.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2352